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1. Introduction 
ACE-inhibitor and angiotensin receptor blocker (ARB)  have been shown to reduce proteinuria 
and progression of renal dysfunction in both type 1 and type 2 diabetics (1-11). However, even 
with optimal use of ACE-Inhibitor or ARB, the progression of renal dysfunction is not 
completely stopped. Even in studies where ACEI or ARB therapy showed improved outcome, 
a very high percentage of patients still progress. This scenario is now highlighted in a recent 
study published in JAMA, which shows the incidence of diabetic nephropathy increasing in 
USA in excess of what can be accounted for by the increased incidence of type 2 DM in the 
population (12). The present treatment strategy is therefore not adequate and other additional 
effective treatment strategies  are urgently needed. 
Since the publication of the landmark RALES study (13) showing a significant survival 
benefit in patients with systolic heart failure when treated with aldosterone inhibition in 
addition to ACEI and beta-blockers, the interest in the vasculotoxic effect of aldosterone and 
the beneficial therapeutic effects of aldosterone receptor blocker drugs like spironolactone 
has been steadily increasing (14). 
2. Aldosterone biology and lessons learnt from animal models 
In addition to its classical action in the distal nephron, aldosterone is now known to exert 
many other effects on other areas of kidneys as well as in cardiovascular tissues. (14 )  
Aldosterone is now known to have a significant role in renal hemodynamics, independent 
of Angiotensin II. In a remnant kidney model in the rat Greene et al showed that there was 
>10-fold rise in aldosterone in the remnant kidney rats  (REM) compared to sham operated 
ones (15). As expected, proteinuria, hypertension and glomerulosclerosis in the REM rats 
were attenuated with treatment using ACE-inhibitor or angiotensin receptor blockers. 
However, when these treated rats (REM AIIA) were given an  aldosterone infusion the 
extent of proteinuria, hypertension and glomerulosclerosis were similar to untreated (REM) 
rats, suggesting deleterious renal hemodynamic effects of aldosterone independent of 
angiotensin II. Use of spironolactone in these rats transiently reduced proteinuria and 
lowered arterial pressure.  
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In rats with 5/6th nephrectomy, adrenalectomy and protein restriction independently 
ameliorated the ablative nephropathy independent of the corticosterone maintenance level 
(16). In stroke-prone spontaneously hypertensive rats (SHRSP), renal vascular injury 
causing proteinuria and malignant nephrosclerotic lesions were markedly reduced by 
treatment with spironolactone (17). The effect of spironolactone alone was comparable to the 
effect of treatment with captopril. In another study the ameliorating effect of ACE-inhibition 
in the SHRSP rats could be fully reversed by infusion of aldosterone, suggesting a major 
additive role for aldosterone in the vascular injury in these rats(18). Importantly, the 
deleterious effects of aldosterone and the protective effects of spironolactone against renal 
damage in SHRSP rats appeared to be independent of the blood pressure. 
Renal damage, as evidenced by albuminuria and glomerulosclerosis, in response to 5/6 
nephrectomy was markedly less in mineralocorticoid resistant Wistar-Furth rats  compared 
to Wistar rats. Treatment of hypertension in the nephrectomized Wistar rats did not protect 
them from renal injury(19), suggesting again that mineralocorticoid mediated deleterious 
effect was independent of the blood pressure. 
Hyperaldosteronism has been noted as a component of clinical chronic renal insufficiency of 
various etiologies including diabetic nephropathy (20-21). In a cross sectional study of patients 
with mild to moderate renal insufficiency, Hene et al observed that the level of serum 
aldosterone increased several fold as creatinine clearance fell below 50% of normal (22). The 
significance of this hyperaldosteronism to the progression of the renal insufficiency has not 
been studied systematically, but in one longitudinal study Walker noted a significant 
correlation between aldosterone level and rate of progression of renal failure (23). In this 
longitudinal cohort study of 131 diabetics, Walker noted that hypertension, plasma angiotensin 
II and aldosterone were independent predictors of accelerated loss of renal function.  
In vitro studies of cultured mesangial cells revealed increased production of type IV 
collagen after incubation with aldosterone (24-25). In addition to the classical genomic action 
through the type 1 mineralocorticoid receptor, aldosterone is now known to have significant 
non-genomic actions in many different tissues including kidney tubules, mesangial cells, 
podocytes and vascular smooth muscle cells. Aldosterone also up-regulates angiotensin II 
membrane receptors thereby multiplying the vascular effect of Ang II. This up-regulation is 
inhibited by treatment with spironolactone (26-30). 
The renoprotective effects of MR blockers have been demonstrated in a variety of animal 
models. While the benefits were seen in most of these models , mechanism of the beneficial 
actions were deemed different in different models, depending on the primary focus of the 
investigators. One area of interest was ACE2  generation. Angiotensin II  (which comes from 
angiotensinogen released by the liver which is converted to inactive Ang I by ACE and then 
to biologically active Ang II) acts mainly through the AT1 receptor to mediate 
vasoconstriction/proliferation and the AT2 receptor which mediates vasodilatation and 
antiproliferation. Ang(1-7) is generated from Ang II by ACE2 and counteracts some of the 
biologic effects of Ang II. In the Dahl-sensitive hypertensive rat fed a high salt diet, 
treatment with epleronone normalized blood pressure and decreased the levels of type IV 
collagen mRNA, angiotensinogen and ACE mRNA, but did not affect ACE2mRNA 
expression and is possibly protective by decreasing the formation of angiotensin II but not 
vasodilatory Ang (1-7). On the other hand, candesartan increased ACE 2 mRNA expression, 
suggesting that aldosterone blockade and angiotensin receptor blockade may be 
complimentary (31). Treatment with epleronone also reduced urinary protein excretion, 
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renal injury scores and decreased (pro)renin receptor protein expression, angiotensinogen 
and AT1R mRNA levels and kidney Ang II content in the same rat model. (32) 
 
 
 
Fig. 1. Angiotensin-Aldosterone Axis and the Physiologic Effects of Aldosterone 
ROS Reactive Oxygen Species, AT1 Angiotensin I, EKODE epoxy-9keto-10trans-
octadecenoic acid, SMC smooth muscle cell  
In the diabetic rat model, spironolactone treatment was associated with a reduction in 
urinary albumin excretion and amelioration of glomerulosclerosis despite no change in 
blood pressure. In various organs including the kidney, there is a local system for 
aldosterone generation. High glucose stimulates the expression of  CYP 11B2 and 
mineralocorticoid receptor. Spironolactone in addition to blockade of the aldosterone 
receptor, was also able to reduce intrinsic renal ACE and also aldosterone synthase gene 
(CYP 11B2) expression in the streptozotocin-induced diabetic mice without affecting blood 
sugar or blood pressure (33).  
Monocyte chemotactic protein (MCP-1) synthesis and nuclear factor-kB are markers of 
inflammation increased in renal tissue and in urine of diabetic rats and patients. In the 
cultured mesangial and proximal tubular cells there was inhibition of urinary excretion of 
MCP-1 (MCP-1) and its upstream transcription factor NF-kB suggesting that aldosterone 
mediated activation of proinflammatory cytokines was blocked (34).  
Transforming growth factor –B1 is a cytokine involved in ECM deposition, proliferation and 
fibrosis. Some of its tissue effects are mediated by connective tissue growth factor (CTGF). 
Aldosterone increases expression of TGF-1 and may directly induce CTGF. Spironolactone 
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reduced TGF-B1 expression and CTGF and renal collagen synthesis through a TGF-B1 
independent pathway (not inhibited by prior TGF-B1 neutralization). (35) 
Plasminogen Activator inhibitor (PAI-1) inhibits fibrinolysis and mediates ECM 
accumulation in mesangial and fibroblast cells and glomerulosclerosis. Its synthesis is 
induced by aldosterone and potentiated by the presence of TGF-B1. Spironolactone 
treatment reduced expression of PAI-1  and TGF-b in streptozotocin-induced diabetic rats 
and improves the antioxidant environment by reducing the fall in superoxide dismutase 
and glutathione peroxidase that accompanies diabetes induction resulting in reduced 
malondialdehyde levels  (lipid oxidation byproduct) (36).  
VEGF is a cytokine involved in the early development of diabetic nephropathy and its 
expression is increased by glucose, AGE, TGF-B1 and IGF-1. Aldosterone infusion increases 
renal VEGF synthesis. Spironolactone alone and in combination with losartan reduced 
VEGF, MCP-1 and malondialdehyde expression resulting in reduced mesangial expansion 
and sclerosis in an OLETF model. (37) 
Aldosterone inhibition was also useful in reducing blood pressure and renal injury in 
diabetic mice which had impaired endothelial nitric oxide response induced by eNOS 
knockout. These mice did not have good response to ACE or ARB therapy. (38). 
Recent studies have also investigated the effects of epleronone alone or in addition to ACE 
or ARB therapy in the diabetic rat. Mineralocorticoid receptor (MR) expression is increased 
in diabetic rats (OLETF) and epleronone reduced cortical levels of MR protein, MR RNA, 
TGF–b mRNA and osteopontin mRNA and improved various histological measures of renal 
injury along with albuminuria (39). The combination of epleronone and enalapril resulted in 
greatest decrease in TGF-b, Type IV collagen and TPA-1 expression both in the whole 
kidney and in cultured mesangial cells accompanied by an improvement in albuminuria, 
GFR and glomerulosclerosis compared to either agent alone. (40). In streptozotocin diabetic 
rats, the addition of epleronone with ramipril prevented glomerular hyperfiltration but did 
not have an additive effect on proteinuria or glomerular hypertrophy (41). Again in OLETF 
diabetic rats, epleronone added to telmisartan did not alter systolic blood pressure but 
resulted in greater reduction in proteinuria and podocyte injury and a greater increase in 
nephrin and podocin mRNA levels. Hydralazine decreased SBP but did not alter any of the 
renal parameters. (42) 
Epleronone protected against podocyte damage in the hypertensive rat model as evidenced 
by reduced expression of podocyte injury markers desmin and B7-1. Mechanisms involved 
include inhibition of NADPH oxidase (p22phox and gp91phox), which is induced by 
aldosterone and generates reactive oxygen species , and reduced aldosterone effector kinase 
Sgk1, which is involved in diabetes stimulated matrix deposition. Unlike epleronone,  
hydralazine did not improve proteinuria or marker expression despite equivalent BP 
control. Local expression of apoptosis related molecules (caspase-3 and Bax) as well as 
reduction of BCl-2 (apoptosis regulatory protein) in podocytes of diabetic rats was 
prevented by treatment  with spironolactone. Based on these studies,  Shibata et al surmised 
that it is possible that Sgk1 plays a key role as the common effector molecule of the MR 
signaling in podocytes. (43-45) 
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During the progression of renal damage, aldosterone might be involved in injury to the 
glomerular podocytes, mesangium, tubulointerstitium and tubules through locally 
expressed Mineralocorticoid receptor (MR).(46-48) However, the precise molecular 
mechanisms responsible for aldosterone and MR-induced cell injury are unclear. In the 
kidney, aldosterone activates multiple intracellular mechanisms including reactive oxygen 
species, mitogen-activated protein kinases (MAPKs) and Rho-kinase etc. by activating 
MR(49-50). These molecular mechanisms have been reviewed recently(51-52). 
The renoprotective effects of spironolactone or epleronone had been seen in many other 
animal models of renal injury  not limited to diabetic nephropathy, as noted in a recent 
review by Nishiyama et al. (46) These models included streptozotocin-induced and other 
forms of diabetic rats and mice, obese SHR rats, murine lupus nephritis, unilateral ureteral 
obstruction, ischemia reperfusion injury, 5/6th nephrectomised rats and rats treated with 
AngII infusion, NO synthase inhibitor or cyclosporine( 53-66). In these animal models, 
treatment with aldosterone blockers had no effect on systemic blood pressure. Thus, these 
observations are consistent with the concept that aldosterone and MR-dependent renal 
injury is not dependent on blood pressure changes but on their local actions. 
Metabolic syndrome with or without diabetes causes podocyte injury and progressive 
nephropathy. In type 2 diabetes, coexistent metabolic syndrome plays a synergistic role in 
progressive renal injury. Nagase et al  investigated the role of aldosterone signaling in rats 
with metabolic syndrome(67). Proteinuria was prominent in SHR/NDmcr-cp compared 
with nonobese SHR, which was accompanied by podocyte injury as evidenced by foot 
process effacement, induction of desmin and attenuation of nephrin. Serum aldosterone 
level, renal and glomerular expression of aldosterone effector kinase Sgk1, and oxidative 
stress markers all were elevated in SHR/NDmcr-cp. Mineralocorticoid receptors were 
expressed in glomerular podocytes. Eplerenone treatment effectively reduced podocyte 
damage, proteinuria, Sgk1, and oxidant stress. Pretreatment with antioxidant tempol also 
alleviated podocyte impairment and proteinuria, along with inhibition of Sgk1.  
When these investigators looked for the source of the excess aldosterone , it was found that 
visceral adipocytes, isolated from SHR/NDmcr-cp, secreted substances that stimulated 
aldosterone production in adrenocortical cells. The aldosterone-releasing activity of 
adipocytes was not inhibited by candesartan. Adipocytes from nonobese SHR did not show 
such activity. That visceral adipocytes may be the source of factors causing excess 
aldosterone was , however, first noted by Ehrhart-Bornstein et al (68) and later the secreted 
factor was further characterized  as EKODE (12,13-epoxy-9keto-10(trans)-octadecenoic acid) 
by Goodfriend et al. (69) These are mainly oxidized polyunsaturated fatty acids produced 
by adipocytes. One of the most potent one is an oxidized product of linoleic acid (EKODE). 
EKODE stimulated aldosteronogenesis at concentrations from 0.5 to 5 micromol/L but 
inhibited it at higher dose. In samples from 24 adults levels of EKODE correlated  directly 
with aldosterone level and in a subsample of 12 blacks in the cohort it correlated with body 
mass index and systolic blood pressure. The resistant hypertension seen in patients with 
abdominal obesity is partly due to these autacoids secreted by visceral adipocytes, and BP in 
these patients respond very well to the use of spironolactone. This may explain the 
observation in the Framingham study that plasma aldosterone concentration was 
significantly correlated with the risk of onset of the metabolic syndrome. 
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Fig. 2. Mechanisms of genomic (long term) and nongenomic (rapid) effects of aldosterone. 
Aldosterone activates the tyrosine kinase c-Src through the production of ROS, leading to the 
activation of p38MAPK and also various signalling molecules like PKC, Akt, ERK ½, ERK5, 
Mapk7, and JNK. Aldosterone also mediates the activation of EGFR. Genomic and rapid 
effects of aldosterone lead to vascularremodeling, hypertrophy, inflammation, cell growth, 
apoptosis, adhesion, and migration. Aldo aldosterone, EGFR epidermal growth factor, MR 
mineralocorticoid receptor, ROS reactive oxygen species. Other abbreviations as in Fig. 1. 
(Ref. 93) 
2.1 Human studies using aldosterone receptor blockers  
Within the past decade, several human studies have been conducted exploring the effects of 
spironolactone and epleronone on patients with chronic kidney disease with or without 
diabetes between which we shall be concentrating on the latter.  
Since ACE-I/ARB therapy had been  generally accepted as standard therapy for patients with 
diabetic nephropathy, most studies conducted with  aldosterone receptor blocker drug  like 
spironolactone involved the addition of this agent to either single agent ACE-I or ARB (referred 
hence to as single- drug add-on) (70-74) or to combined ACE-I/ARB therapy (dual-drug add-
on) (75-76). Epleronone likewise has been tested as add-on therapy to enalapril (77-78).  
In one study (79), albeit in non-diabetic patients, where spironolactone was compared head-
to-head to the ACE-I drug cilazapril along with the combination, it was found that 
spironolactone was slightly better at reducing albuminuria than cilazapril, but the 
www.intechopen.com
Diabetic Nephropathy: Role of Aldosterone and  
Benefits of Therapy with Aldosterone Receptor Blocker 47 
combination resulted in a further reduction. The blood pressure reduction was the same 
among the three groups. 
A review of the studies where spironolactone was used as single-drug or dual-drug add-on, 
the degree of albuminuria or proteinuria reduction was about 30-35% with a trend towards 
a further reduction in studies that had an extended period of observation of up to a year 
(76). The reduction in albuminuria was greater when spironolactone was used as single-
drug add on compared to dual-drug add on (although one study (80) reported an 
impressive 58% reduction). The addition of spironolactone to baseline ACE-I (lisinopril) 
therapy resulted in greater reduction in albuminuria compared to the addition of an ARB 
agent (losartan) to baseline ACE-I (74). This was confirmed in another study that 
demonstrated that the addition of spironolactone to either single-drug (ramipril) or dual-
drug (ramipril + irbesartan)  baseline therapy resulted in further reduction in albuminuria 
but  the addition of ARB alone to the ACE-I did not further reduce albuminuria. (75). 
Several  studies correlated the degree of proteinuria reduction to a drop in GFR and to the 
preexisting serum aldosterone level. Urinary type IV collagen, which is stimulated by 
aldosterone and is a reflection of renal fibrosis, was also decreased. (73,80) 
The efficacy of spironolactone as add-on agent in patients with uncontrolled hypertension 
specifically those with features of aldosterone excess, such as obesity and low serum 
potassium levels, has been demonstrated in several studies . The reduction of systolic BP in 
these studies exceeds 20 mmHg. In the studies we are reviewing on diabetic nephropathy, 
most of whom again, were already on preexisting ACE-I and ARB therapy, the focus of the 
aldosterone antagonist add-on was on proteinuria and renal function. The reduction in BP 
was more modest. When used as single-agent add-on, several studies show a drop of 6-8 
mmHg in systolic BP or ABPM with an additional smaller reduction with longer followup. 
One study showed no further drop in blood pressure, but this group of patients had overall 
a very high GFR (73). Addition of epleronone to enalapril produced only a non-significant 
change in BP (22). Spironolactone used as dual-drug add-on generally did not further 
reduce BP (75). There has been controversy among researchers in the field as to whether the 
reduction in proteinuria with aldosterone antagonists is a result purely of further BP 
lowering, but these studies demonstrate that it is much easier to show a reduction of 
proteinuria that is statistically significant compared to a reduction in blood pressure. 
The study results regarding the effects of aldosterone antagonists on renal function must be 
interpreted with caution. First of all, most of the studies followed renal function through 
measurement of serum creatinine or an estimation of GFR mathematically derived from 
creatinine levels, and it is well recognized that this is an insensitive marker to small changes 
in renal function. One exception are the studies from Denmark (26) which actually 
measured GFR directly. Secondly, the studies all excluded patients with Stage 4 and 5 CKD., 
and in fact the mean baseline GFR in most studies exceeded 60 ml/minute, and there are not 
enough patients in Stage 3 CKD to really draw any meaningful conclusions as to the effects 
of aldosterone antagonists on patients with more advanced CKD. With these caveats, the 
published studies indicate that the effect of spironolactone or epleronone on GFR is 
comparable to the effect of initiation of ACE-I or ARB agents . Single-drug add-on in most 
studies resulted in a 3-5 ml/min drop in GFR, while dual-agent add-on caused no further 
drop in GFR. The effects are most prominent in the first month or two after initiation, and 
drop in GFR is greater in those with baseline impaired function. One study in particular 
showed a sharp 13 ml/min decrease in GFR with spironolactone compared to baseline ACE-
I or ARB therapy, but this decrease occurred early and eventually leveled off. Associated 
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with this was a sharp drop in albuminuria of 40%. Many studies confirm that the reduction 
in proteinuria correlates well with the degree in reduction of GFR. 
Most of the adverse effects noted includes the known incidence of anti-androgenic effects of 
spironolactone and hyperkalemia which correlates with the dosage used. Epleronone is of 
course, free of the first set of side effects and generally results in less hyperkalemia, but this 
may be a function of the dosages currently being studied . Most studies excluded patients 
with baseline potassium exceeding 4.5 or 5.0 mmol/L. The trend of the results show that 
while dual-agent therapy had a greater tendency towards hyperkalemia when compared to 
single agent therapy, the addition of spironolactone to either ACE-I or ARB resulted in the 
highest risk of hyperkalemia. This complication may be more frequent  among diabetics 
who tend to have hyporeninemic hypoaldosteronism and is definitely more prevalent in 
patients with lower baseline GFR, higher baseline potassium, and preexisting metabolic 
acidosis. With the background of the experience after publication of the RALES study, when 
practitioners promoted the use of spironolactone for heart failure in patients outside the 
inclusion criteria of the study, resulting in the appearance of several near fatal hyperkalemic 
episodes, it behooves us to follow the patients with more advanced CKD more closely and 
to check serum potassium agents earlier if we choose to use these agents for diabetic 
nephropathy. There was a suggestion that glucose tolerance worsened after spironolactone 
with a rise in Hba1c (70,81)), but this was not seen in other studies (78). Spironolactone may 
also decrease BNP over that achieved by ACE-I (84).  
A small study conducted by these authors(82) using a randomized double-blind crossover 
design to study the effects of spironolactone when added to ACE-I or ARB  shows similar 
results to the studies quoted above, in that spironolactone produced a 57% reduction in 
proteinuria along with a 7mmHg drop in systolic BP. This was accompanied by a rise in 
creatinine of about 0.2 mg/dl and serum potassium of 0.3 mEq/L.  
The role of aldosterone antagonists in the treatment of diabetic nephropathy may lie in the 
group of patients whose blood pressure or proteinuria are uncontrolled despite ACE-I or ARB 
therapy, or who manifest so-called ‘aldosterone escape” when aldosterone levels increase after 
long-term RAAS blockade. (83-84)). Table 1 lists all the clinical trials using Aldosterone 
receptor blockers in proteinuric patients. As shown in the table the range of proteinuria 
reduction with additional use of aldosterone receptor blocker was 19% to 58%.(70-87) 
Aldosterone antagonists seem to be more effective and more economical when added to ACE-I 
compared to ARBs at this time, albeit at the price of greater risk for acute GFR drop and 
hyperkalemia. Unfortunately, no long term studies are available at this time to demonstrate 
that renal function decline is slowed by this approach, and proteinuria is taken as a marker of 
disease progression, as was with ACE-I/ARB therapy at an earlier time point. 
3. Future direction 
The beneficial effects of mineralocorticoid/aldosterone receptor blockers  in ameliorating or 
stopping the progression of diabetic nephropathy is impressive in in-vitro studies using 
mesangial, podocytes or endothelial cell culture system. These studies also help us 
understand the molecular mechanism by which these agents ameliorate the pathologic 
process. In-vivo animal model studies also showed encouraging results as elaborated in 
preceding pages. Similar benefits have been seen in human studies as summarized in the 
table 1. However most of the human studies were of relative short duration. Longest study 
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Author/Year 
No. of Patients/ 
Design of Study
Drugs/Dose/ 
Duration (Weeks) 
Reduction in 
Proteinuria (%) 
In 
Sys.BPmmHg/ 
GFRml/min/ 
Kmeq/L 
     
Chrysostomou / 
2001 
8 / Uncontrolled SP / 25 / 4 54%  
Epstein / 2002 
141/(74 + 67) 
RCT–Parallel 
EP / 200 / 12 19% 3/ - / - 
Rachmani /2004
60/RCT- 
Parallel 
SP / 100 / 24 19% -- 
Sato / 2005 
32 / 
Uncontrolled 
SP / 25 / 12 38% - / - / ↑0.1 
Bianchi / 2005 
42 / 
Uncontrolled 
SP / 25 / 8 37% - / - / ↑0.4 
Schjoedt / 2005
20 / RCT-
Crossover 
SP / 25 / 8 30% ↓8 / - / - 
Rossing / 2005 
21 / RCT- 
Crossover 
SP / 25 / 8 33% ↓6 / ↓ 3 / - 
Van den 
Meiracker / 2006
59 (29 + 30) 
RCT-Parallel 
SP / 25-50 / 8 41% ↓7 / ↓ 8 / - 
Schjoedt / 2006
20 / RCT- 
Crossover 
SP / 25 / 8 32% ↓6 / ↓ 3 /↑0.2 
Chrysostomou 
/2006 
41 / RCT- 
Parallel 
SP / 25 / 12 
(4 group) 
14% ↓9/ - /↑0.2 
Bianchi / 2006 
165  (82 + 83) 
RCT–Parallel 
SP / 25 / 52 58% - / ↑ ↓ /↑ 0.8 
Epstein/2006 
268/RCT-
Parallel 
Ep/50-100/12 
41%(high dose) 
34%(low dose) 
↓4 / ↓ 6 / - 
Ogawa 2006 30/RCT SP / 25 / 52 47% ↓11/ - / - 
Furumatsu 2008 25/RCT SP / 25 / 52 58% / - / - 
Saklayen 2008 
24/RCT- 
Crossover 
SP / 25 / 12 57% ↓12 / ↓8 / ↑0.3 
Davidson 2008 24/Uncontrol SP / 25 / 4 26% ↓9 / - / - 
Mehdi 2009 81/ RCT SP/ 25 / 52 52% / - / ↑ 
Legend: Table showing summaries of the clinical studies done with aldosterone receptor blocker in 
addition to ACE inhibitor or ARB use in proteinuric patients. 
Table 1. 
follow up was 1 year. And none of these studies examined the long term renal outcomes, 
especially progression to ESRD, need for dialysis or overall mortality. This paucity of 
clinical outcome studies is of major concern. Of note, when clinical studies of short duration 
showed additional lowering of microalbuminuria/proteinuria in diabetic nephropathy as 
well as in other proteinuric renal diseases, nephrologists became enthusiastic about dual use 
of ACEI and ARB in patients with diabetic nephropathy. When the large international 
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ONTARGET study showed that renal outcomes (GFR deterioration, incidence of ESRD, 
need for dialysis  and incidence of hyperkalemia) in diabetic nephropathy of patients on 
dual therapy was worse than on single agent  therapy ( ACEI or ARB alone), that initial 
enthusiasm was checked. (88) Dual ACEI and ARB use is no longer recommended  in 
patients with diabetic nephropathy except in  extraordinary situations. 
However, the long term outcomes of MR/aldo blocker therapy with ACEI or ARB in 
diabetic nephropathy need not be similarly detrimental or non-beneficial. Of note while 
ONTARGET failed to show cardiovascular benefits with dual ACEI and ARB use and other 
studies showed lack of mortality benefits in dual use of ACEI and ARB in systolic heart 
failure(89), RALES and other studies (90) showed significant mortality benefit of adding 
spironolactone or epleronone to ACE or ARB  in systolic heart failure patients. However, 
unless large clinical outcome studies confirm that adding aldosterone blockade to ACEI or 
ARB  actually results in reduction of ESRD incidence, such therapy cannot be recommended 
without some caution. 
When we did our small cross over study in a single institute, we selected patients carefully. 
Those patients who had hyperkalemia , even remotely, were excluded from participation. 
Most of our patients also were using high dose thiazide or loop diuretics. Our study, like 
many other similar studies,  were of few weeks duration. As shown in POST RALES study, 
the incidence of hyperkalemia in Ontario  was much higher than seen in the RALES study 
itself , when spironolactone use became widespread for systolic heart failure. (91) 
Questions often arise  if one were to use an aldosterone receptor blocker, which one to choose. 
Spironolactone is the first mineralocorticoid receptor antagonist (MRA) which has been in 
clinical use for over half a century. Epleronone is a relatively new mineralocorticoid receptor 
blocker and is still  under patent protection. Compared to the latter, spironolactone blocks the 
androgen  and progesterone receptors in addition to its primary blocking effects on 
mineralocorticoid receptors. This leads to some unpleasant problem of gynecomastia in male 
patients, the incidence of which is about 10%. Epleronone is much less likely to cause 
gynecomastia. But binding affinity of epleronone for MR is much lower than that of 
spironolactone. Spironolactone also has 3 active metabolites all of which have prolonged half 
life. Epleronone has half life of4-6 hours and its metabolites are not active. Because of these 
pharmacological and pharmacodynamic differences, spironolactone seems to be a clinically 
more effective MR blocking agent than epleronone. One recent comparison of treatment with 
spironolactone (75 to 225 mg daily ) vs epleronone (100 to 300 mg daily) in patients with 
primary hyperaldosteronism showed better blood pressure lowering by spironolactone 
(diastolic BP  reduction 12.5 mmHg in former vs 5.6 mmHg in later group). There has not been 
a head to head comparison of the two MR blockers  in trials looking for  a reduction of 
proteinuria or improvement in survival in patients with systolic dysfunction. (92) 
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